← Human Trials & Peer-Reviewed Studies
Changes in pain and insulin-like growth factor 1 in fibromyalgia during exercise: the involvement of cerebrospinal inflammatory factors and neuropeptides
Plain-language guide to PMID 22776095 (2012): randomized controlled trial study of IGF-1 LR3 in 49 patients.
Key Facts
- PMID
- 22776095
- Journal
- Arthritis research & therapy
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Bjersing JL et al. (5 authors)
- DOI
- 10.1186/ar3902
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in this randomized controlled trial publication.
The aim was to examine changes in serum IGF-1, cerebrospinal fluid (CSF), neuropeptides, and cytokines during aerobic exercise in FM patients.
Why It Was Studied
Fibromyalgia (FM) is characterized by chronic pain.
Who Took Part
The study group was 49 patients.
The age groups tagged for this paper are middle-aged adults, women only.
In total, 49 patients (median age, 52 years) with FM were included in the study.
Patients participated in blood tests before and after 15 weeks of aerobic exercise.
How the Study Was Run
In design terms this was a randomized study.
Because people in this IGF-1 LR3 study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The timeline in the abstract includes 15 weeks.
They were randomized to either the moderate- to high-intensity Nordic Walking (NW) program (n = 26) or the supervised low-intensity walking (LIW) program (n = 23).
Changes in serum levels of free IGF-1, pain rating on a 0- to 100-mm scale, pain threshold, and 6-minute walk test (6MWT) were examined.
CSF, neuropeptides, matrix metalloproteinase 3 (MMP-3), and inflammatory cytokines were determined.
Nonparametric tests were used for group comparisons and correlation analyses.
What Was Measured
PubMed files the paper under topics including Biomarkers, Exercise, Fibromyalgia, Inflammation Mediators, Insulin-Like Growth Factor I, Neuropeptides and Pain.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 49 patients over 15 weeks.
Results are reported in around 9 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2012 (Arthritis research & therapy), a journal based in England.
More context: the IGF-1 LR3 compound page, all human trials.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.